EU approves Novartis’ SMA gene therapy Zolgensma
Discussions with EU governments and reimbursement agencies are ongoing to agree on terms of an innovative ‘Day One’ access programme
Read More
Tag: AveXis
Novartis snaps up AveXis in $8.7bn deal
Novartis is buying US gene therapy group AveXis in a deal valued at $8.7 billion.
Read More
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
